Feasibility and population exposure of 5‐fluorouracil using therapeutic drug monitoring (PREDICT‐5FU): A multicentre clinical trial
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Sarah Glewis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Australia. Hauptthemen laut MEDLINE: Antimetabolites, Antineoplastic, Drug Monitoring, Fluorouracil. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Council New South Wales, Cancer Council NSW.
Abstract (Originalsprache)
Aim
PREDICT‐5FU aimed to document 5‐fluorouracil (5FU) exposure in a cancer population and to evaluate the feasibility of 5FU and capecitabine therapeutic drug monitoring (TDM) in patients receiving standard doses and schedules.
Methods
Multicentre, prospective, observational single‐arm study. Eligible adult patients received 5FU (infusional ≥24 h) or capecitabine. Patients were treated for gastrointestinal, breast and head‐and‐neck cancers at four Australian hospitals. TDM was performed in consecutive cycles until target area under the curve (AUC) was reached. Pharmacogenetic testing was performed for all patients.
Results
Fifty patients (24 males, 26 females) were recruited. Median age was 63 years; common diagnoses were lower gastrointestinal cancers 40% (20/50) and metastatic disease 80% (40/50). The majority received 5FU (38/50, 76%) over 46 h. Only 36% of 5FU patients achieved target AUC when dosed based on body surface area; 61% were below and 3% above target range. Post TDM‐adjusted dosing, target AUC was achieved in 58% of patients (22% absolute increase vs . BSA dosing, p = 0.03), within median three cycles (range 1–5). DPYD variant allele carriers (3/4) had upfront reduced dosing due to heterozygosity; all were below the target AUC and one experienced Grade 3 toxicity. There was no correlation between dihydrouracil: uracil ratio [UH2/U] or uracilemia [U] and DPYD genotype. TDM results were reported with an average of 4 days from sampling.
Conclusion
TDM dosing is feasible and increases the proportion of patients reaching target AUC. Findings are relevant across all cancers treated with 5FU, and particularly for DPYD variant allele carriers receiving upfront dose reductions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Faculty of Medicine and Health Sciences, Macquarie University, New South Wales, Australia.
- Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
- School of Medicine and Public Health, University of Newcastle, New South Wales, Australia.
ORCID-Profile: Sarah Glewis
Förderung
- Cancer Council New South Wales
- Cancer Council NSW
Zitieren
APA
Glewis, S., Michael, M., Gurney, H., Olver, I., Zdenkowski, N., Ackland, S., Kukard, C., Jayawardana, M., Silva, S. S. M., Alexander, M., Tie, J., Galettis, P., & Martin, J. H. (2025). Feasibility and population exposure of 5‐fluorouracil using therapeutic drug monitoring (PREDICT‐5FU): A multicentre clinical trial. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70006
Vancouver
Glewis S, Michael M, Gurney H, Olver I, Zdenkowski N, Ackland S, et al. Feasibility and population exposure of 5‐fluorouracil using therapeutic drug monitoring (PREDICT‐5FU): A multicentre clinical trial. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70006
BibTeX
@article{Glewis2025,
author = {Glewis, Sarah and Michael, Michael and Gurney, Howard and Olver, Ian and Zdenkowski, Nicholas and Ackland, Stephen and Kukard, Craig and Jayawardana, Madawa and Silva, S Sandun M and Alexander, Marliese and Tie, Jeanne and Galettis, Peter and Martin, Jennifer H},
title = {Feasibility and population exposure of 5‐fluorouracil using therapeutic drug monitoring (PREDICT‐5FU): A multicentre clinical trial},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70006}
}
EUVIMED